ISS Study Links Psychiatric Medication to False Positive Fentanyl Tests

Routine drug screenings face fresh scrutiny following scientific findings that commonplace psychiatric medications can trigger incorrect alerts for powerful synthetic narcotics. The research, published in Clinical Chemistry and Laboratory Medicine, demonstrates that rapid urine test kits used to detect fentanyl are vulnerable to chemical cross-reactivity when patients undergo standard therapeutic treatments, raising wider questions across the sector about workplace testing, institutional screening accuracy, and healthcare integrity.

The investigation was spearheaded by researchers at the National Center for Addictions and Doping at the Istituto Superiore di Sanità (ISS). According to study authors Manuela Pellegrini and Annagiulia di Trana, medical staff in mental health services noticed that multiple patients registered positive for fentanyl via rapid urine tests despite lacking any clinical history of use. Subsequent multi-substance laboratory screening of these samples revealed the presence of risperidone — a pharmaceutical prescribed for psychiatric disorders — and valproic acid, utilized for epilepsy and mood regulation.

To isolate the interfering agent, researchers introduced the drugs separately and in combination to clean urine samples. The experimental results confirmed that risperidone alone, as well as combined with valproic acid, caused rapid tests to generate false positive readings for fentanyl at therapeutic concentrations. Valproic acid administered in isolation produced no such interference.

Manuela Pellegrini and Annagiulia di Trana explained that cross-reactivity occurs because the test can confuse one substance with another and report a positive result that does not correspond to the presence of fentanyl, as reported by La Milano. Simona Pichini, director of the National Center for Addictions and Doping at the ISS, warned that such erroneous outcomes risk generating unwarranted suspicion of illicit drug use, damaging patient relationships with healthcare providers, and distorting medical care decisions.

The vulnerability of rapid screening technology extends far beyond clinical psychiatry, echoing systemic issues documented in correctional and employment settings where preliminary kits guide high-stakes administrative policies. A prominent example emerged from New York City's Rikers Island jail complex, where the Department of Correction utilized rapid test kits, initially manufactured by Sirchie and later by DetectaChem, to combat suspected contraband mail. According to an investigation by the New York City Department of Investigation, those field tests exhibited false positive rates soaring between 85% and 91%. Department of Investigation Commissioner Jocelyn Strauber noted that the flawed data vastly overstated the presence of drug-laced letters, which had previously fueled sweeping proposals to ban physical mail and replace it with electronic scans.

Similar vulnerabilities affect standard workplace, athletic, and legal drug screenings. Various everyday substances, over-the-counter medications, and health conditions regularly compromise preliminary drug panels by generating metabolite cross-reactivity.

As outlined in guidance compiled regarding workplace drug testing, the legal and professional repercussions of unverified false positives can prove severe, threatening employment security, professional licensure, and personal reputation. Experts emphasize that robust safeguards, such as maintaining transparent personal medication logs, notifying testing administrators of legitimate prescriptions, and exercising the right to confirmatory testing using Gas Chromatography-Mass Spectrometry, remain essential defenses against administrative error.

What happens next depends on how testing administrators, healthcare providers, and regulatory agencies respond to accumulating data on cross-reactivity. Public health officials continue to stress that preliminary rapid screens must be treated strictly as initial indicators rather than conclusive evidence. As laboratories refine analytical protocols and institutions re-evaluate field testing reliability, patients and employees facing unexpected screening results are urged to demand secondary verification before punitive measures or clinical alterations are enacted.